AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical ...
Drug giant AstraZeneca updated its data on how well its coronavirus vaccine works, saying late Wednesday the vaccine showed 76% efficacy against symptomatic coronavirus disease and 100% efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback